Marina Chiara Garassino to Bevacizumab
This is a "connection" page, showing publications Marina Chiara Garassino has written about Bevacizumab.
Connection Strength
0.387
-
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat Rev. 2019 May; 75:39-51.
Score: 0.157
-
Bevacizumab for non-small-cell lung cancer. N Engl J Med. 2007 Mar 29; 356(13):1373; author reply 1374-5.
Score: 0.068
-
Development and clinical indications of cetuximab. Int J Biol Markers. 2007 Jan-Mar; 22(1 Suppl 4):S40-6.
Score: 0.067
-
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial. J Thorac Oncol. 2022 09; 17(9):1086-1097.
Score: 0.049
-
Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol. 2012 Oct; 23(10):2771-2772.
Score: 0.025
-
Risk/benefit profile of bevacizumab in metastatic colon cancer: a systematic review and meta-analysis. Dig Liver Dis. 2011 Apr; 43(4):286-94.
Score: 0.022